Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
Johnson and Johnson
McKesson
Mallinckrodt

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TOREMIFENE CITRATE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Toremifene Citrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00106691 Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) Completed GTx Phase 3 2005-01-01 The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).
NCT00129142 Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy Completed GTx Phase 3 2003-10-01 Androgen deprivation therapy (ADT) treatment for prostate cancer decreases the natural hormone called testosterone. This type of therapy is very effective for the treatment of prostate cancer. However, one of the side effects is bone loss or thinning of the bones that can lead to osteoporosis and an increased risk of bone fractures (breaking of the bones). The purpose of the study is to determine whether or not the addition of toremifene citrate (the study drug) to therapy can prevent or decrease the number of bone fractures and to evaluate its impact on side effects associated with testosterone reduction therapy.
NCT00437359 Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer Terminated Japan Breast Cancer Research Network Phase 2 2007-05-01 To investigate the benefit of postoperative adjuvant therapy using sequential administration of the hormone, toremifene citrate (TOR) or anastrozole (ANA), after chemotherapy in breast cancer.
NCT01214291 Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer Withdrawn Ipsen Phase 3 2011-03-01 The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.
NCT01214291 Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer Withdrawn GTx Phase 3 2011-03-01 The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.
NCT02017197 Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Fundação de Amparo à Pesquisa do Estado de São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Toremifene Citrate

Condition Name

Condition Name for Toremifene Citrate
Intervention Trials
Postmenopausal 1
Stage IA Breast Cancer 1
Osteoporosis 1
Stage 0 Breast Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Toremifene Citrate
Intervention Trials
Prostatic Neoplasms 3
Breast Neoplasms 2
Fractures, Bone 2
Prostatic Intraepithelial Neoplasia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Toremifene Citrate

Trials by Country

Trials by Country for Toremifene Citrate
Location Trials
United States 59
Mexico 7
Canada 3
Brazil 1
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Toremifene Citrate
Location Trials
Washington 3
Michigan 2
Texas 2
Colorado 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Toremifene Citrate

Clinical Trial Phase

Clinical Trial Phase for Toremifene Citrate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Toremifene Citrate
Clinical Trial Phase Trials
Completed 3
Not yet recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Toremifene Citrate

Sponsor Name

Sponsor Name for Toremifene Citrate
Sponsor Trials
GTx 3
Federal University of São Paulo 1
Fundação de Amparo à Pesquisa do Estado de São Paulo 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Toremifene Citrate
Sponsor Trials
Other 4
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Mallinckrodt
Dow
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.